This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Panzem NCD

CASI Pharmaceuticals, Inc.

Drug Names(s): 2ME2 NanoCrystal Colloidal Dispersion, 2ME2, 2-methoxyestradiol, 2-ME2

Description: Panzem is Entremed's third anti-angiogenic agent in development. It is a natural estrogen metabolite with anti-angiogenic properties. It was discovered in Dr. Judah Folkman's lab by looking for natural products made by pregnant mothers during late stages of pregnancy.

EntreMed has reformulated 2ME2 as an orally-administered liquid suspension (Panzem NCD) to increase plasma drug levels in patients. Panzem NCD uses Elan Drug Delivery’s (Elan) NanoCrystal Colloidal Dispersion (NCD), a proprietary technology that is being used successfully in marketed pharmaceuticals. The NCD technology produces nanometer-sized particles that are up to 50 times smaller than particles manufactured by conventional pharmaceutical milling techniques. In preclinical toxicity studies, the liquid suspension formulation demonstrated no additional toxicity.

Deal Structure: Elan Corporation and EntreMed announced in January 2006 that that they entered into a License Agreement in which EntreMed has been granted rights to utilize Elan's proprietary NanoCrystal Technology to develop Panzem NCD.Under the terms of the License Agreement, Elan is eligible to receive payments upon the achievement of certain clinical, manufacturing, and regulatorymilestones. Additionally, Elan will receive royalty payments based on sales of Panzem NCD.

Under the License Agreement and corresponding Services Agreement, Elan will manufacture EntreMed's Panzem NCD.

Perrigo and Elan
In December 2013, Perrigo and Elan announced that Perrigo has completed the acquisition of Elan in a cash and stock transaction valued on the date of the announcement at approximately US$8.6 billion. In connection with the acquisition, Perrigo and Elan have been combined under a new company incorporated in Ireland and have adopted the global name Perrigo Company plc. Shares of Perrigo will...See full deal structure in Biomedtracker

Partners: Perrigo Company PLC


Panzem NCD News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug